SCHEMBL6000283

SCHEMBL6000283

CN(c1ccncc1)c1cccc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.48
KDM4C Q9H3R0 1/20 0.47
HTR3E A5X5Y0 1/20 0.46
HTR3B O95264 1/20 0.46
HTR3A P46098 1/20 0.46
HTR3D Q70Z44 1/20 0.46
HTR3C Q8WXA8 1/20 0.46
GRM5 P41594 1/20 0.45
TAAR1 Q96RJ0 2/20 0.44
CSNK2A2 P19784 1/20 0.43
CSNK2B P67870 1/20 0.43
CHKA P35790 3/20 0.43
CHRM5 P08912 1/20 0.43
EGFR P00533 3/20 0.43
CSF1R P07333 3/20 0.43
MAPT P10636 1/20 0.42
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28322173 0.84 HTR3E (0.52) GRM4HTR3EHTR3BHTR3AHTR3D
SCHEMBL2218837 0.82 CHKA (0.49) KDM4CCHKACHRM5MAPTMEN1
SCHEMBL13367477 0.79 KDM4C (0.46) KDM4CCHKACHRM5EGFRCSF1R
SCHEMBL2222390 0.78 CHKA (0.52) KDM4CCHKACHRM5MAPTMEN1
SCHEMBL5998795 0.78 GRM5 (0.45) GRM5TAAR1CHKACHRM5EGFR
SCHEMBL6000218 0.78 ABCG2 (0.46) KDM4CTAAR1CHKACHRM5KMT2A
SCHEMBL2223507 0.78 CHKA (0.56) CHKACHRM5EGFRMAPTMEN1
SCHEMBL3409151 0.77 CHRM5 (0.68) CHKACHRM5MAPTMEN1KMT2A
SCHEMBL6000381 0.76 CHRM5 (0.45) TAAR1CHKACHRM5MAPTMEN1
SCHEMBL17602063 0.75 RELA (0.50) KDM4CHTR3EHTR3BHTR3AHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4855308-A Method of treating senile cognitive decline with N'-substituted aminopyridine adrenergic agents WARNER-LAMBERT COMPANY (US) 1989-08-08 US claimed
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke K AND K BIOSCIENCE, INC. (US) 2006-03-16 US disclosed
US-4855308-A Method of treating senile cognitive decline with N'-substituted aminopyridine adrenergic agents WARNER-LAMBERT COMPANY (US) 1989-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke SIGMAR1, GRM1, GRIN2C GRM4 31/4885KDM4C 2307/4885HTR3E 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.